The Immunogenicity of OMP31 Peptides and Its Protection Against Brucella melitensis Infection in Mice

Fengbo Zhang1, Zhiwei Li2, Bin Jia3, Yuejie Zhu3, Pan Pang4, Chuntao Zhang4 & Jianbing Ding4

Given brucellosis is a widespread zoonosis in the world, a safe and effective vaccine is urgently needed. Recent trend in vaccine design has shifted to epitope-based vaccines that are safe and specific. In this study, peptide containing both T-cell and B-cell epitopes of OMP31 was synthesized and used to immunize the mice by nasal administration. The protective efficacy was evaluated. Mice immunized with the B epitope or TB epitope peptides of OMP31 had higher levels of IgG1 and IgG2a in the serum. While the BALB/c mice immunized with peptides containing T cell epitope or TB epitope of OMP31 showed high degree of IFN-γ-producing T cells in the lymphocytes from the respiratory draining lymph nodes and spleen. After intranasally challenged with 5 × 10^5 CFU of Brucella melitensis (strain 16 M), the bacterial loads in lung of the immunized mice were significantly lower than control group. These data demonstrate for the first time that peptides of OMP31 containing T epitope, B epitope or TB epitopes are of high immunogenicity and thus can protect host from Brucella melitensis infection in lung.

Brucellosis is a widespread zoonosis caused by Brucella species and can induce severe illness in humans and substantial economic losses in livestock1–4. Brucella melitensis (B. melitensis) are the main causative agents of Brucellosis in humans. The disease has a tendency towards chronicity and persistence, which can develop into a granulomatous disease capable of affecting any organ system. The timely and accurate diagnosis of human brucellosis continues to challenge clinicians because of its non-specific clinical features, slow growth rate in blood cultures, and the complexity of its sero-diagnosis.

Human brucellosis poses significant economic and health concerns in Mediterranean areas, the Middle East, South and Central America and Asia. There are more than 500,000 cases reported annually worldwide5,6. In livestock, brucellosis is responsible for reproductive loss resulting from abortion, birth of weak offspring, or infertility.

Brucella can cause the infection via the mucosal surface of the host. For livestock, the main route of exposure is by ingestion or inhalation of microorganisms. Infection in humans occurs mainly by consumption of contaminated milk and meat products, contact with fluids of infected animals and inhalation of infectious aerosols7,8. What is shared between animal and human Brucella transmission is the naso-oropharyngeal mucosa being impacted by Brucella, but not the intestinal mucosa. Hence, a vaccine aimed at inducing the respiratory system mucosal immune response has a high potential for success. Unfortunately, there is still no available human brucellosis vaccine. All commercially available animal vaccines are based on live attenuated strains of Brucella that can induce abortions in pregnant animals and are potentially infectious to humans9–11.

Owing to the disadvantages of live attenuated vaccines, replacing these vaccines by peptide ones would be a great improvement for safety reasons. An ideal peptide vaccine should include multivalent B cell epitopes and T cell epitopes to elicit high humoral immunity and cell immunity response12,13. Peptide vaccines have been found to be effective in preventing diseases, such as Chlamydia trachomatis14, foot-and-mouth disease15 and Mycobacterium tuberculosis16. Several Brucella components have been used as vaccines against brucellosis. Previous study indicates that peptide vaccine designed based on Brucella components could provide protection against brucellosis17.

The 31KDa outer membrane protein (Omp31) is a major membrane protein of Brucella and plays an important role in the pathogenesis of brucellosis. The Omp31 is a promising target for the development of Brucella vaccine. Recent studies have demonstrated that Omp31 contains both T-cell and B-cell epitopes required to elicit the humoral and cell-mediated immune responses18,19. In this study, we synthesized and used peptides containing both T-cell and B-cell epitopes of Omp31 to immunize mice by nasal administration. The protective efficacy of these peptide vaccines was evaluated. Mice immunized with the B epitope or TB epitope peptides of Omp31 had higher levels of IgG1 and IgG2a in the serum. While the BALB/c mice immunized with peptides containing T cell epitope or TB epitope of Omp31 showed high degree of IFN-γ-producing T cells in the lymphocytes from the respiratory draining lymph nodes and spleen. After intranasally challenged with 5 × 10^5 CFU of Brucella melitensis (strain 16 M), the bacterial loads in lung of the immunized mice were significantly lower than control group. These data demonstrate for the first time that peptides of Omp31 containing T epitope, B epitope or TB epitopes are of high immunogenicity and thus can protect host from Brucella melitensis infection in lung.

1Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China. 2Department of Clinical Laboratory, The People Hospital of Xinjiang, Urumqi, 830001, Xinjiang, China. 3Reproductive Medicine Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, Xinjiang, P.R. China. 4Department of Immunology, College of Basic Medicine of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China. Fengbo Zhang, Zhiwei Li and Bin Jia contributed equally. Correspondence and requests for materials should be addressed to J.D. (email: 1601379937@qq.com)
role in conferring the protection against *B. melitensis*. Although Omp31 is of great potential as an antigen for vaccination, it is also an important virulence factor of *Brucella* species. One alternative of Omp31 vaccine is to develop peptide vaccine, which can be immunized by nasal administration and provide protection in the respiratory tract. In this study, we analyzed T cell and B cell epitopes of OMP31 by bioinformatics. Then we synthesized the corresponding epitopes and used them as vaccines to immunize mice. The effects of OMP31 peptide vaccines on the immune response and protection against *B. melitensis* infection were evaluated in mice model.

**Results**

Immunization with peptides containing B epitope and TB epitope induces specific systemic humoral immunity and mucosal immunity of respiratory tract. To verify whether peptides containing B epitope, T epitope or TB epitope could promote the humoral immune response, we immunized mice with different peptides, respectively. The serum was collected and the levels of specific IgG1 and IgG2a antibodies were measured by ELISA. Both IgG1 and IgG2a in mice immunized with B peptide, T epitope or TB epitope were significantly higher than those of PBS control group (*P* < 0.01) (Fig. 1A). To further explore the major T cell types in different peptides immunized mice, we compared the levels of IgG2a/IgG1 ratio. The results showed that IgG2a/IgG1 ratio in mice immunized with B peptide or TB epitope was significantly higher than that in PBS control group (*P* < 0.01) and T epitope (*P* < 0.05) (Fig. 1B), indicating that the T cell immune response is biased towards Th1 reaction in the B peptides and TB peptides immunized mice. To investigate whether the respiratory mucosal immune response is also activated by peptides containing B epitope, T epitope or TB epitope, we examined the level of secretory IgA (sIgA) in the bronchoalveolar lavage fluid. As shown in Fig. 1C, the sIgA level after immunization with peptides containing T epitope, B epitope and TB epitope was significantly higher (*P* < 0.05). Additionally, the sIgA level in the mice immunized with peptides containing T epitope and TB epitope was significantly lower than that of the B epitope immunization group (*P* < 0.05). These results indicate that peptides containing B epitope and TB epitope could promote specific systemic humoral immunity and mucosal immunity of respiratory tract.

**T epitope or TB epitope containing peptides induces specific T cell immunity.** To analyze whether peptides containing T epitope, B epitope or TB epitope could activate the T cell immune response, the lymphocytes in the respiratory draining lymph nodes and spleen were isolated from the peptides immunized mice. And the specific T cell responses were tested by IFN-γ ELISPOT assay after stimulation with heat-killed RB51 (HKB51) or ConA. PBS and SAG4 peptide were used as negative controls. As shown in Fig. 2A,B the IFN-γ secreting T cells of the respiratory lymph nodes and splenocytes in T peptides and TB peptides immunized mice
were significantly higher than those of PBS group \((P < 0.01)\) or SAG4 peptide group \((P < 0.01)\). There was no significant difference between PBS group and SAG4 peptide group \((P > 0.05)\). These data indicate that peptides containing T epitope or TB epitope can induce specific T cell immunity.

**Peptide immunization provides partial protect against* B. melitensis* infection in lung but cannot confer protection against its dissemination.** To determine whether the T epitope, B epitope or TB epitope had a protective effect against* B. melitensis* infection, the immunized mice were challenged with* B. melitensis*. Then the lung and spleen cells were isolated for the bacterial culture. Compared with the control group in lung, the bacterial loads of the immunized mice were significantly lower \((P < 0.05)\) (Fig. 3) and there is no significant difference between T epitope, B epitope or TB epitope immunized groups \((P > 0.05)\). However, when compared with the bacterial load in spleen, there was no significant difference between these groups. These results indicate that T epitope, B epitope or TB epitope immunization could protect mice from* B. melitensis* infection in lung but cannot confer protection against its dissemination.
Discussion
Here, in this study, we first demonstrated that OMP31 peptides were of high immunogenicity, which could induce both humoral immunity and Th1 cell response dramatically. Furthermore, we observed that OMP31 peptides could protect the host from Brucella melitensis infection.

OMP31 contains both B cell and T cell epitopes. To further study the immunogenicity of the peptide, we synthesized peptides containing T epitopes, B epitopes or TB epitopes and then immunized mice intranasally. We found that the levels of IgG1 and IgG2a in serum of B cell epitope and TB epitope immunized mice were higher than those in control group. And, IgG2a/IgG1 ratio in the immunized mice was higher. Specific antibodies have been used as important indicators for evaluating candidate vaccines31. Clausse, M. et al. have synthesized rBLSOmp31 and found the protein could induce IgG2a and IgG1 responses in the immunized mice32. Similarly, Brucella Omp2b protein is found to induce humoral immune responses and the production of IgG2a33. In this study, we found that Brucella peptides could also induce the humoral immune response of the body. Since Brucella infections can be acquired through mucosal membranes including respiratory tract, we would like to know whether peptides can induce the local mucosal immune response through intranasal administration. The results demonstrated that peptides containing B cell epitope and TB epitope could elicit the mucosal IgA response. IgA represents the hallmark of mucosal immune response. Moreover, IgA also protect the host by binding to the surface of luminal microbes and toxins to prevent them from attaching to epithelial cells34. Therefore, vaccination with peptides containing B cell epitope and TB epitope through intranasal administration induced the antibody immune response and mucosal immunity of respiratory tract.

We found that the humoral immune response in mice immunized with B and TB epitopes was dominated by the IgG2a subtype. Studies have reported that IgG2a is mainly associated with Th1 profiles, and resistance to Brucella depends on enhanced Th1 immunity35,36. In this study, we also tested if Omp31 peptide could induce the Th1 immune response in mice by using IFN-γ ELISPOT. The lymphocytes in the respiratory draining lymph nodes and spleen from T epitope and TB epitope immunized mouse were stimulated by heat-killed RB51 in vitro. We found that the number of IFN-γ producing T cells was significantly increased, which indicates that peptides containing T epitope and TB epitope could efficiently induce Th1 immune response. Recent studies have used Brucella antigen Omp2b37 and Omp3138 to develop vaccines for Brucella and found that Th1 immune response could be induced. However, these candidate vaccines were not peptide-based vaccines. Alley, P. et al. have used a synthesized T cell polypeptide to induce the Th1 immune response38. Similarly in this study, we found that the peptides containing T epitope and TB epitope could activate IFN-γ producing T cells in respiratory draining lymph nodes and spleen. As such, the data presented here, argue that the peptides containing T epitope and TB epitope of Omp31 could induce the Th1 immune response. Importantly, for the first time, we identified the TB epitope of Omp31 and found that it could induce both humoral and Th1 immune responses.

To evaluate the protective capacity of peptides containing T cell epitope, B cell epitope and TB epitope, we used a mouse model challenged with Brucella melitensis. We found that bacterial loads in the lungs of the T cell epitope, B cell epitope and TB epitope immunized mice were significantly lower, indicating that T cell epitope, B cell epitope and TB epitope immunization could provide partial protection against Brucella infection in lung. However, this was not observed in the spleen. We speculate that this difference may be related to the different immune responses between the lung (respiratory tract) and the spleen. Studies have found that the immune response of respiratory tract in mice not only enhances T cell immune responses in murine pulmonary mucosa and the whole body, but also promotes the secretion of more specific sIgA in the respiratory tract mucosa39-40. In addition, we found that sIgA level in the bronchoalveolar lavage fluid was increased after immunization with peptides containing T epitope, B epitope and TB epitope. Therefore, we suppose that in the lungs, not only the cellular immune response is activated, but also sIgA is produced. However, in the spleen, there is no such response. In summary, our results demonstrate that peptides containing T epitope, B epitope and TB epitope have strong immunogenicity and can induce both Th1 immune response and humoral immune response, thus providing protection against Brucella melitensis infection in lung. These data presented in this study have important ramifications for the development of effective mucosal Brucella vaccines in future.

Materials and Methods
Animals. BALB/c mice (6 weeks old, female, 10 for each group) were purchased from the animal center of Xinjiang Medical University (Urumqi, Xinjiang, China). Mice were kept in standard condition with free access to food and water. All animal experiments were conducted according to the ethical guidelines of State Key Laboratory Incubation Base of Xinjiang Major Diseases Research All animal experiments in this study were performed in accordance with the Guidelines for Animal Experimentation and were approved by the Animal Research Committee of Xinjiang Medical University (approval number A-20130216-155). Epitope prediction and analysis. We predicted the T cell epitope of OMP31 with SYFPEITHI (http://www.syfpeithi.de/) and ProPred Prediction Server (http://www.imtech.res.in/raghava/propred1/). The B cell epitope of OMP31 was predicted using DNAstar (USA lyonnon biosoft) and IEDB software (http://tools.immuneepitope.org/bce1). The predicted T cell, B cell epitopes and TB epitopes of OMP31 (Table 1) were synthesized by Shanghai Qiannya Biotechnology (Shanghai, China). The amino acid sequences shared by T cell epitopes and B cell epitopes were defined as TB epitopes.

Immunization and B. melitensis Challenge. The process of immunization and B. melitensis challenge was shown in Fig. 4. BALB/c mice were randomly divided into four groups, including control group, T group, B group, TB group. Mice were immunized intranasally (i.n., 15μL per nostril) with PBS (Control group), 30μg T epitopes (T epitope group), B epitopes (B epitope group) and TB epitopes (TB epitope group), respectively, for 0, 15, 30, and 45 days. All animal experiments with live B. melitensis were performed in BASL-3 facility. To assess
the protective effect of T cell epitopes, B cell epitopes and TB epitopes, mice were infected with $5 \times 10^5$ CFU *B. melitensis* (strain 16 M) by intranasal infection at 30 days after the last immunization. At 14 days post infection, all mice were sacrificed by cervical dislocation after inhalation of isoflurane. The respiratory lymph nodes (head, neck, and lower respiratory lymph node) and spleen was removed under sterile conditions and the homogenate was prepared for cell isolation. The trachea was cannulated, and the lungs were gently lavaged 3 times with 1 mL of sterile PBS to obtain bronchoalveolar lavage fluid. Blood was collected from the retro-orbital sinus using a Pasteur capillary pipette without anticoagulant and placed in coagulation microtubes. After centrifugation, serum was collected.

**ELISA.** To detect the immunogenicity of T cell epitope, B cell epitope and TB epitope of OMP31. Antigen-specific IgG1 and IgG2a titers in the immunized mice were tested by ELISA. Briefly, the T epitope, B epitope and TB epitope (1 $\mu$g/ml) were coated on 96-well polystyrene plate (Greinerbio-one, Frickenhausen, Germany) at 100 $\mu$L/well and incubated at 4 °C overnight. The plate was rinsed with TBS-T (Tris-buffered saline, pH 7.4, containing 0.05% Tween-20) for 4 times, followed by blocking with PBS containing 10% fetal bovine serum (FBS) at 37 °C for 2 h. Then, 100 $\mu$L of mouse serum diluted at 1:100 was added to the well and incubated at room temperature for 2 h. After rinsing, horseradish peroxidase conjugated goat-anti-mouse IgG1 or IgG2a antibodies (BD Pharmingen, Santiago, USA) were added and then incubated at 37 °C for 1 h. Substrate solution (BD OptEiA, BD Pharmingen, Santiago, USA) was added to each well. After 10 min of incubation at room temperature, 20% H$_2$SO$_4$ was added to terminate the reaction. The absorbance value was measured using a microplate reader (Bio-Tropsch Tek Instruments, Winooski, Vt., USA) at a wavelength of 405 nm.

For measurement of sIgA, 96-well plates were coated with 0.25 g/well peptide (T epitope, B epitope and TB epitope) overnight at 4 °C. The bronchoalveolar lavage fluid (1:5 dilution) were added in triplicate into wells of the plates and incubated for 1 h at 37 °C. After washing, horseradish peroxidase conjugated goat anti-mouse IgA (1: 1,000 dilutions; KPL) was added and incubated for 1 h. Then reactions were completed by addition of the substrate as described above.

**Preparation and culture of mouse respiratory lymph node cell and splenocytes.** Respiratory lymph nodes (head, neck, and lower respiratory lymph node) and spleens were harvested, cut into small pieces. Single-cell suspensions were prepared by mechanically dispersing the tissues through 70-μm cell strainers (Falcon BD Labware) and the cells were suspended in 10 mL PBS containing 5 mM EDTA. The mononuclear cells were isolated by Ficoll-Paque density gradient centrifugation. Then, the mononuclear cells were cultured in RPMI-1640 medium (RPMI-1640 supplemented with 2 mM l-glutamine, 100 U/mL penicillin, 100 g/mL streptomycin and 10% heat inactivated FBS) at 37 °C, 5% CO$_2$.

**IFN-γ ELISPOT.** ELISPOT plates were coated with anti-mouse IFN-γ capture antibody (BD PharMigen, San Diego, CA) diluted 1:60 in PBS at 4 °C, overnight. The plate was then washed four times with PBST and once with PBS. Plates were blocked with 100 μL of RPMI-1640 medium containing 10% fetal calf serum for 1 h at 37 °C. The
respiratory lymph nodes cells and splenocytes were added at a final concentration of 1 × 105/well in a final volume of 100μL. Cells were stimulated with the heat-killed RB51 (10μg/mL) (a source of Brucella protein without LPS), synthetic Toxoplasma SAG4 peptide (10μg/mL), ConA (10μg/mL) at 50μL/well and PBS at 50μL/well was used as the positive and negative controls, respectively. Then the plates were incubated at 37 °C with 5% CO2 for 24 h. After washing, 50μL of biotin-labeled secondary antibody (BD Pharmigen, San Diego, CA) was added and the plate was incubated at room temperature for 2 h. Then, the plates were washed with PBST and 50μL streptavidin alkaline phosphatase (Amersham Life Science, Australia) was added and incubated at room temperature for 2 h. The spots were developed by adding BCIP/NBT developer (Moss, Inc, Pasadena, MD, USA) to each well for incubation for 40 min at room temperature. At last, plates were washed in water to stop reaction and the spots were counted using an ELISPOT Bio Reader-4000 (BIOSYS, GmbH, Germany).

**Analysis of Brucella CFUs.** Lung and spleen were suspended in 1 ml of 0.9% normal saline containing 0.1% Triton X-100 and mechanically homogenized in tissue grinders. A total of 20μl of undiluted homogenates and serial 10-fold dilutions of homogenates were inoculated on tryptic soy agar plates and incubated for 3–4 days at 37°C in 5% CO2. Brucella CFUs were enumerated. The results were presented as the mean log10 CFU ± SD per group.

**Statistics.** The data were analyzed by SPSS 13.0. When the data were normal distribution, they were shown as mean ± SD. In this study, one-way ANOVA was used for analysis in experiments with more than two groups. And student t test was used when there were two groups in experiments. When the data was non-normal distribution, rank sum test was used. A P < 0.05 was considered statistically significant.

**References**

1. Huy, T. X. et al. Intracellular trafficking modulation by ginsenoside Rg3 inhibits Brucella abortus uptake and intracellular survival within RAW 264.7 cells. J. Microbiol. Biotechnol. (2016).
2. Pang, P. et al. Increased serum levels of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients infected with Brucella. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 32, 1675–1678 (2016).
3. Zhang, H. et al. Expression and regulation of the opr operon of Brucella melitensis in human trophoblast cells. Exp. Ther. Med 12, 2723–2728 (2016).
4. Sofian, M. et al. Interlukine-17 and TGF-β levels in patients with acute brucellosis before and after treatment. Turk. J. Med. Sci. 46, 1348–1352 (2016).
5. de Figueiredo, P. et al. Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions. Am. J. Pathol 185, 1505–1517 (2015).
6. Fan, P. et al. Bioinformatics analysis of T- and B-combined epitopes of OMP31 protein of Brucella melitensis in Xinjiang, China. Int. J. Clin. Exp. Med. 10, 13320–13330 (2017).
7. Tumwine, G. et al. Human brucellosis: sero-prevalence and associated risk factors in agro-pastoral communities of Kiboga District, Central Uganda. BMC. Public. Health. 15, 900 (2015).
8. Pang, P. et al. The changes of sTim-3/HMG1R and Spot forming cells of TGF-β secreting from peripheral blood mononuclear cell in patients infected with brucella. Chinese Journal of Immunology. 1 (2017).
9. Schurig, G. et al. Brucellosis vaccines: past, present and future. Vet. Microbiol. 90, 479–496 (2002).
10. Godfroid, J. Brucellosis at the animal/ecosystem/human interface at the beginning of the 21st century. Prev. Vet. Med. 102, 118–131 (2011).
11. Lalsiamthara, J. et al. Development and trial of vaccines against Brucella. J. Vet. Sci. 18, 281–290 (2017).
12. Zahiroh, H. et al. Immunoinformatics Approach in Designing Epitope-based Vaccine Against Meningitis-inducing Bacteria (Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae Type b). Drug. Target. Insights. 10, 19–29 (2016).
13. Verma, S. K. et al. In silico prediction of B- and T- cell epitope on Lassa virus proteins for peptide based subunit vaccine design. Adv. Biomed. Res. 4, 201 (2015).
14. Ganda, I. S. et al. Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection. Int. J. Pharm. 527, 79–91 (2017).
15. Blanco, E. et al. Full protection of swine against foot-and-mouth disease by a bivalent B-cell epitope dendrimer peptide. Antiviral. Res. 129, 74–80 (2016).
16. Carabali-Isajar, M. L. et al. Towards designing a synthetic antituberculosis vaccine: The Rv3587c peptide inhibits mycobacterial entry to host cells. Biog. Med. Chem. 26, 2401–2409 (2018).
17. Zhi, M. et al. Development of a multi-epitope peptide vaccine inducing robust T cell responses against brucellosis using immunoinformatics based approaches. Infect. Genet. Evol. 51, 227–234 (2017).
18. Zhang, K. et al. OMP31 of Brucella melitensis 16M impairs the apoptosis of macrophages triggered by TNF-α. Exp. Ther. Med. 12, 2783–2789 (2016).
19. Ma, Q. et al. Brucella outer membrane protein Omp25 induces microglial cells in vitro to secrete inflammatory cytokines and inhibit apoptosis. Int. J. Clin. Exp. Med. 8, 17530–17535 (2015).
20. Yao, L. et al. Immunogenic response to a recombinant pseudorabies virus carrying bp26 gene of Brucella melitensis in Mice. Res. Vet. Sci. 100, 61–67 (2015).
21. Sano, G. et al. Characterization and Evaluation of Newly Developed Immune-Chromatographic Method Targeting Mycoplasma pneumoniae Ribosomal Protein L7/L12. J. Med. Microbiol. 2016 (2016).
22. Francis, N. et al. CitA Controls Cell Division and Outer Membrane Composition of the Pathogen Brucella abortus. Mol. Microbiol (2016).
23. Ghasemi, A. et al. Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection. Vaccine. 33, 5532–5538 (2015).
24. Vizcaíno, N. et al. Cloning, nucleotide sequence, and expression of the Brucella melitensis omp31 gene coding for an immunogenic major outer membrane protein. Infect. Immun. 64, 3744–3751 (1996).
25. Clausse, M. Evaluation of the efficacy of outer membrane protein 31 vaccine formulations for protection against Brucella canis in BALB/c mice. Clin. Vaccine. Immunol. 21, 1689–1694 (2014).
26. Amani, J. et al. Immune reactivity of sera obtained from brucellosis patients and vaccinated-rabbits to a fusion protein from Brucella melitensis. Iran. J. Basic. Med. Sci. 18, 350–355 (2015).
27. Vizcaíno, N. et al. Molecular characterization of a Brucella species large DNA fragment deleted in Brucella abortus strains: evidence for a locus involved in the synthesis of a polysaccharide. Infect. Immun. 67, 2700–2712 (1999).
28. Naseri, Z. et al. Prevalence of the Most Common Virulence-Associated Genes among Brucella Melitensis Isolates from Human Blood Cultures in Hamadan Province, West of Iran. Iran. J. Med. Sci. 41, 422–429 (2016).
29. Golshani, M. et al. Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen. *Mol. Immunol.* **66**, 384–391 (2015).
30. Golshani, M. et al. Vaccination with recombinant L7/L12-truncated Omp31 protein induces protection against Brucella infection in BALB/c mice. *Mol. Immunol.* **65**, 287–292 (2015).
31. Vitry, M. A. et al. Humoral immunity and CD4+ Th1 cells are both necessary for a fully protective immune response upon secondary infection with Brucella melitensis. *J. Immunol.* **192**, 3740–3752 (2014).
32. Clauss, M. et al. The vaccine candidate B1SOmp31 protects mice against Brucella canis infection. *Vaccine*. **2013**, 6129–6135 (2013).
33. Golshani, M. et al. Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against Brucella infection using Omp2b in BALB/c Mice. *Vet. Microbiol.* **199**, 9–16 (2017).
34. Afley, P. N. et al. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems. *J. Immunol.* **199**, 9–16 (2017).
35. Qi, C. et al. Prediction of T cell epitopes of Brucella abortus using artificial neural network. *Appl. Microbiol. Biotechnol.* **99**, 7625–7637 (2015).
36. Yang, D. et al. A novel recombinant multi-epitope protein against Brucella abortus infection. *Immunol. Lett.* **175**, 1–7 (2016).
37. Dai, X. et al. Co-delivery of polynosinic:polycytidylic acid and flagellin by poly(lactic-co-glycolic acid) MPs synergistically enhances immune response elicited by intranasally delivered hepatitis B surface antigen. *Int. J. Nanomedicine.* **12**, 6617–6632 (2017).

**Acknowledgements**

The work was supported by National Natural Science Foundation of China (81560322), Postdoctoral Foundation of China (2017M613261), Science and Technology training Project of Urumqi-Young Doctor of Science and Technology Training Program, and the 13th Five-year Plan for Key Disciplines in XinJiang.

**Author Contributions**

Conceived and designed the experiments: Jianbing Ding. Performed the experiments: Fengbo Zhang, Zhiwei Li, Bing Jia and Chuntao Zhang. Analyzed the data: Yuejie Zhu and Pan Pang. Wrote the manuscript: Fengbo Zhang and Jianbing Ding.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019